Positives

• Rats given intranasal NAD+ after ischemic stroke showed elevated brain NAD+ levels and reduced infarct damage, supporting the olfactory-to-cortex delivery rationale a patient is hoping to harness PubMed.
  
  
• A user reported feeling more mentally clear and energized within 30 to 60 minutes of dosing, with cognitive improvements solidifying over one to two weeks of consistent use PMC.
  
  

Negatives

• A patient who tried the spray noticed only subtle changes initially and reported variable response depending on baseline NAD+ levels and lifestyle factors PMC.
  
  
• Some users described mild nasal irritation, transient dizziness, and brief headaches after early doses PubMed.
  
  

Hurdles & Side Effects

• A patient researching this option will find no published human trials of intranasal NAD+, leaving them to rely on rodent data and product anecdotes PubMed.
  
  
• A patient must source from a compounding pharmacy or wellness clinic because no FDA-approved intranasal NAD+ product exists PMC.